In vitro and in vivo metabolism of a novel p38 kinase inhibitor

TOXI 138

Kaushik Mitra, kaushik_mitra@merck.com1, Koppara Samuel1, Swaminathan Natarajan2, and Sanjeev Kumar1. (1) Department of Drug Metabolism, Merck Research Laboratories, Rahway, NJ 07065, (2) Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07095
P38, a MAP kinase known to mediate inflammatory pathways, is a biological target for developing treatments for rheumatoid arthritis. This presentation will focus on drug metabolism properties of a novel p38 kinase inhibitor, and will include discussion on its pharmacokinetics, bioactivation chemistry, and in vitro and in vivo metabolism.
 

General Papers
1:00 PM-4:45 PM, Wednesday, August 22, 2007 BCEC -- 258C, Oral

Division of Chemical Toxicology

The 234th ACS National Meeting, Boston, MA, August 19-23, 2007